Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development $ 5,483 $ 2,909
General and administrative 10,222 2,101
Settlement expense   21,366
Reimbursement of expenses from Relief Therapeutics   (771)
Total operating expenses 15,705 25,605
Loss from operations (15,705) (25,605)
Other (income) expenses:    
Gain on extinguishment of debt   (121)
Interest expense 3 5
Change in fair value of warrant liability (157)  
Change in fair value of Earnout Cash liability (2,103)  
Total other (income) expenses (2,257) (116)
Net loss $ (13,448) $ (25,489)
Net loss per share:    
Basic $ (0.21) $ (0.71)
Diluted $ (0.20) $ (0.71)
Weighted average common shares outstanding:    
Basic 63,667,468 35,658,216
Diluted 63,667,468 35,658,216